Status:
ACTIVE_NOT_RECRUITING
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Lead Sponsor:
AbbVie
Conditions:
Parkinson's Disease (PD)
Eligibility:
All Genders
30+ years
Phase:
PHASE3
Brief Summary
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremor...
Eligibility Criteria
Inclusion
- \- Completion of the parent study, Study M15-736 or Study M20-339.
Exclusion
- \- Participant considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason.
Key Trial Info
Start Date :
February 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2026
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT04750226
Start Date
February 18 2021
End Date
April 1 2026
Last Update
August 12 2025
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham - Main /ID# 217814
Birmingham, Alabama, United States, 35233
2
University of South Alabama /ID# 218467
Mobile, Alabama, United States, 36604-3302
3
Xenoscience, Inc /ID# 222515
Phoenix, Arizona, United States, 85004
4
Muhammad Ali Parkinson Center /ID# 218609
Phoenix, Arizona, United States, 85013-4407